EP3615022B1 - Petites molécules organiques destinées à être utilisées dans le traitement de troubles neuroinflammatoires - Google Patents
Petites molécules organiques destinées à être utilisées dans le traitement de troubles neuroinflammatoires Download PDFInfo
- Publication number
- EP3615022B1 EP3615022B1 EP18791845.3A EP18791845A EP3615022B1 EP 3615022 B1 EP3615022 B1 EP 3615022B1 EP 18791845 A EP18791845 A EP 18791845A EP 3615022 B1 EP3615022 B1 EP 3615022B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- bmp
- cells
- disease
- eae
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000011282 treatment Methods 0.000 title claims description 42
- 208000036110 Neuroinflammatory disease Diseases 0.000 title claims description 20
- 201000006417 multiple sclerosis Diseases 0.000 claims description 54
- 150000001875 compounds Chemical class 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 239000003814 drug Substances 0.000 claims description 14
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 11
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 83
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 74
- 230000000694 effects Effects 0.000 description 48
- 241000699670 Mus sp. Species 0.000 description 41
- 201000002491 encephalomyelitis Diseases 0.000 description 34
- 238000000034 method Methods 0.000 description 33
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 26
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 26
- 150000003384 small molecules Chemical class 0.000 description 26
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 25
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 22
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 22
- 229940112869 bone morphogenetic protein Drugs 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 230000000638 stimulation Effects 0.000 description 19
- 239000003981 vehicle Substances 0.000 description 19
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 17
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 17
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 16
- 229930002330 retinoic acid Natural products 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 15
- 229960001727 tretinoin Drugs 0.000 description 15
- 208000016192 Demyelinating disease Diseases 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 230000011664 signaling Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 10
- 108090000192 Methionyl aminopeptidases Proteins 0.000 description 10
- 238000004166 bioassay Methods 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 10
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 9
- 206010012305 Demyelination Diseases 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 9
- 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 9
- 230000004069 differentiation Effects 0.000 description 9
- 238000013537 high throughput screening Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 210000003141 lower extremity Anatomy 0.000 description 9
- 230000001537 neural effect Effects 0.000 description 9
- 238000011002 quantification Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 102000006386 Myelin Proteins Human genes 0.000 description 8
- 108010083674 Myelin Proteins Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 208000015122 neurodegenerative disease Diseases 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- -1 cationic salts Chemical class 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 239000010432 diamond Substances 0.000 description 7
- 239000003937 drug carrier Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 210000005012 myelin Anatomy 0.000 description 7
- 230000004766 neurogenesis Effects 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000002516 postimmunization Effects 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000002233 Myelin-Oligodendrocyte Glycoprotein Human genes 0.000 description 6
- 108010000123 Myelin-Oligodendrocyte Glycoprotein Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 208000027905 limb weakness Diseases 0.000 description 6
- 231100000861 limb weakness Toxicity 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 description 5
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108010072051 Glatiramer Acetate Proteins 0.000 description 4
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 description 4
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 4
- 102000004243 Tubulin Human genes 0.000 description 4
- 108090000704 Tubulin Proteins 0.000 description 4
- 230000001668 ameliorated effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960000556 fingolimod Drugs 0.000 description 4
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002055 immunohistochemical effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000004020 luminiscence type Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 102000045246 noggin Human genes 0.000 description 4
- 108700007229 noggin Proteins 0.000 description 4
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 108010081690 Pertussis Toxin Proteins 0.000 description 3
- 101700032040 SMAD1 Proteins 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 238000000423 cell based assay Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 208000010726 hind limb paralysis Diseases 0.000 description 3
- 102000045896 human BMP2 Human genes 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000023105 myelination Effects 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 108010005716 Interferon beta-1a Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 102000016202 Proteolipids Human genes 0.000 description 2
- 108010010974 Proteolipids Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000012911 assay medium Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000012054 celltiter-glo Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940038717 copaxone Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229960004419 dimethyl fumarate Drugs 0.000 description 2
- 230000009266 disease activity Effects 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 229960003776 glatiramer acetate Drugs 0.000 description 2
- 102000046148 human BMP4 Human genes 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 150000003854 isothiazoles Chemical class 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- TYAUIXPYQSXZBS-OQLLNIDSSA-N methyl 3-[(2e)-2-[cyano(thiophen-2-ylsulfonyl)methylidene]hydrazinyl]thiophene-2-carboxylate Chemical compound S1C=CC(N\N=C(/C#N)S(=O)(=O)C=2SC=CC=2)=C1C(=O)OC TYAUIXPYQSXZBS-OQLLNIDSSA-N 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003007 myelin sheath Anatomy 0.000 description 2
- 229960005027 natalizumab Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 210000003757 neuroblast Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000002314 neuroinflammatory effect Effects 0.000 description 2
- 208000008795 neuromyelitis optica Diseases 0.000 description 2
- 230000004031 neuronal differentiation Effects 0.000 description 2
- 210000003458 notochord Anatomy 0.000 description 2
- 229950005751 ocrelizumab Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
- 229940079023 tysabri Drugs 0.000 description 2
- OCYPFRDEUKBLNI-UHFFFAOYSA-N 1,2-thiazole-4-carbonitrile Chemical compound N#CC=1C=NSC=1 OCYPFRDEUKBLNI-UHFFFAOYSA-N 0.000 description 1
- BICGOULMPJLRQV-MYINAIGISA-N 1-[(2s,4s,5r)-2-bromo-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO)O[C@@]1(Br)N1C(=O)NC(=O)C=C1 BICGOULMPJLRQV-MYINAIGISA-N 0.000 description 1
- DJALIOOHHCVQKU-UHFFFAOYSA-N 2-(3-acetamido-3-oxopropyl)sulfanyl-n-acetylbenzamide Chemical compound CC(=O)NC(=O)CCSC1=CC=CC=C1C(=O)NC(C)=O DJALIOOHHCVQKU-UHFFFAOYSA-N 0.000 description 1
- VBLXCTYLWZJBKA-UHFFFAOYSA-N 2-(trifluoromethyl)aniline Chemical compound NC1=CC=CC=C1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- VEYRTZVLYXCVCX-UHFFFAOYSA-N 3,6-diphenyl-1,4-dihydro-1,2,4,5-tetrazine Chemical compound N1N=C(C=2C=CC=CC=2)NN=C1C1=CC=CC=C1 VEYRTZVLYXCVCX-UHFFFAOYSA-N 0.000 description 1
- AAXPHZSTFUDCNF-UHFFFAOYSA-N 4-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)-n-[4-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound O=C1C(C=23)=CC=CC3=CC([N+](=O)[O-])=CC=2C(=O)N1C(C=C1)=CC=C1S(=O)(=O)NC1=CC=C(C(F)(F)F)C=C1 AAXPHZSTFUDCNF-UHFFFAOYSA-N 0.000 description 1
- HHABHUIQGJHIIZ-UHFFFAOYSA-N 5-(4-chlorophenyl)-3-methylsulfonyl-1,2-oxazole-4-carbonitrile Chemical compound CS(=O)(=O)C1=NOC(C=2C=CC(Cl)=CC=2)=C1C#N HHABHUIQGJHIIZ-UHFFFAOYSA-N 0.000 description 1
- XRYAGGCLDGQPOK-UHFFFAOYSA-N 5-nitro-n-[3-(trifluoromethyl)phenyl]furan-2-carboxamide Chemical compound O1C([N+](=O)[O-])=CC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 XRYAGGCLDGQPOK-UHFFFAOYSA-N 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 208000035859 Drug effect increased Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010005714 Interferon beta-1b Proteins 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 102100025725 Mothers against decapentaplegic homolog 4 Human genes 0.000 description 1
- 101710143112 Mothers against decapentaplegic homolog 4 Proteins 0.000 description 1
- 101100293255 Mus musculus Plp1 gene Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 102000055324 Myelin Proteolipid Human genes 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 229940057415 aubagio Drugs 0.000 description 1
- 229940003504 avonex Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940112129 campath Drugs 0.000 description 1
- 230000008758 canonical signaling Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000035194 endochondral ossification Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 230000005936 hippocampal cell proliferation Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000037456 inflammatory mechanism Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000003140 lateral ventricle Anatomy 0.000 description 1
- 229940047834 lemtrada Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 210000005230 lumbar spinal cord Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- XRTSQEYCWCLLDE-CXUHLZMHSA-N methyl 4-cyano-3-[(2e)-2-[cyano(thiophen-2-ylsulfonyl)methylidene]hydrazinyl]thiophene-2-carboxylate Chemical compound S1C=C(C#N)C(N\N=C(/C#N)S(=O)(=O)C=2SC=CC=2)=C1C(=O)OC XRTSQEYCWCLLDE-CXUHLZMHSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000010004 neural pathway Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000007511 neuronal proliferation Effects 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000032724 odontogenesis Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 208000010713 partial hind limb paralysis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940038850 rebif Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008886 response to retinoic acid Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940121136 tecfidera Drugs 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 229960000331 teriflunomide Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000028048 ureteric bud development Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/345—Nitrofurans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- This invention relates to the field of therapeutics of neurodegenerative and neuroinflammatory diseases.
- Small organic molecules that may act as inhibitors of bone morphogenetic proteins (BMPs) are disclosed as useful in the treatment of neuroinflammatory disorders, in particular multiple sclerosis.
- BMPs bone morphogenetic proteins
- MS Multiple sclerosis
- BMPs Bone morphogenetic proteins
- WO 2013/186777 discloses pharmaceutical compositions for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several blocking agent(s) of BMP signaling.
- US 2015/139983 discloses methods for the treatment of neuroinflammatory or neurodegenerative diseases comprising a single or a combination of several antibodies directed against BMP-2 and BMP-4.
- US 2008/0249038 [4] discloses a method of alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues, whether resulting from tissue trauma, or from chronic or acute degenerative changes, using a BMP2A inhibitor, in particular siRNA molecules or antisense molecules.
- Simonini et al. [5] examined effects of the PPAR ⁇ (peroxisome proliferator-activated receptors) agonist GW0742 on OPCs (oligodendrocyte progenitor cells), and showed that GW0742 reduced BMP2 and BMP4 mRNA levels in OPCs, with lesser effects in astrocytes. Simonini et al. concluded that PPAR ⁇ plays a role in OPC maturation, mediated, in part, by regulation of BMP and BMP antagonists.
- PPAR ⁇ peroxisome proliferator-activated receptors
- Li et al. [6] evaluated hippocampal cell proliferation in the DG subgranular zone (DG-SGZ), and BMP4 mRNA level, in the APPsweIPS 1 DeltaE9 transgenic mouse, a mouse model of Alzheimer's disease.
- the investigators found a significant correlation between an increased BMP4 mRNA expression and a decreased number of BrdU labeled cells and suggested that the increased expression of BMP4 mRNA within the DG of the hippocampus may contribute to the decrease in cell proliferation in APPsweIPS 1 DeltaE9 transgenic mice.
- WO 11/019678 discloses the use of isothiazoles for treating conditions of the eye, e.g. age related macular degeneration.
- US 2006/217390 [12] discloses cycloalkyl, aryl and heteroaryl amino isothiazoles for the treatment of hepatitis C.
- WO 03/105857 [13] discloses pharmaceutical compositions containing active compounds, which inhibit the activity of the chemokines, MIP-1 alpha and RANTES. It is also directed to methods of treating inflammatory diseases using these pharmaceutical compositions.
- US 2004/039037 [14] discloses substituted isothiazole compounds directed towards inhibition of various protein kinases (especially MEK and/or ERK). It is also directed to methods of treatment of diseases associated with abnormality in MEK and/or ERK function.
- BMPs bone morphogenetic proteins
- small organic molecules capable of inhibiting BMP2 with an IC50 lower than 10 ⁇ M are provided. According to further aspects of the invention, small organic molecules capable of inhibiting both BMP2 and BMP4 are provided. According to yet further aspects small organic molecules capable of inhibiting BMP2 are provided in pharmaceutical compositions useful for the treatment neuroinflammatory diseases, including but not limited to multiple sclerosis.
- the present invention is based in part on the finding that small organic compounds of the Formula (Ia), as well as specific compounds designated herein SM1, SM6, SM7 and SM9 inhibited the activity of bone morphogenetic protein 2 (BMP2) in a cell based assay. Furthermore, these molecules inhibited disease progression in an animal model of relapsing/remitting experimental autoimmune encephalomyelitis (RR-EAE), a well-established model mimicking multiple sclerosis (MS). Without wishing to be bound by any particular theory of a mechanism of action, these small organic molecules appear to induce neurogenesis and oligodendrogenesis, and to maintain the amount of myelin, by inhibiting demyelination, inducing remyelination, or both.
- BMP2 bone morphogenetic protein 2
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of Formula (Ia) or a salt thereof: wherein X 1 and X 2 are each independently S; X 3 is CN; X 4 , X 5 , X 6 , X 7 , and X 8 are each H; R 1 is H; and R 3 is OR 5 , wherein R 5 is methyl or ethyl.
- a method of treating a neuroinflammatory disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having the general Formula (Ia) or a salt thereof, wherein X 1 and X 2 are each independently S; X 3 is CN; X 4 , X 5 , X 6 , X 7 , and X 8 are each H; R 1 is H; and R 3 is OR 5 , wherein R 5 is methyl or ethyl.
- a compound having the general Formula (Ia) or a salt thereof wherein X 1 and X 2 are each independently S; X 3 is CN; X 4 , X 5 , X 6 , X 7 , and X 8 are each H; R 1 is H; and R 3 is OR 5 , wherein R 5 is methyl or ethyl.
- the compound is having the formula SM1:
- the pharmaceutical composition is for use in the treatment of a neuroinflammatory disease.
- the pharmaceutical composition further comprises an additional therapeutic agent.
- the neuroinflammatory disease is multiple sclerosis.
- the multiple sclerosis is relapsing remitting multiple sclerosis.
- the method further comprises the administration of an additional therapeutic agent to said subject.
- the additional therapeutic agent is administered prior to, concomitantly, or following the administration of the at least one compound, or a pharmaceutical composition comprising said at least one compound.
- the pharmaceutical composition comprises the compound SM1.
- the present invention provides small organic molecules capable of inhibiting BMPs that show therapeutic utility in inhibiting EAE, in particular a relapsing form of EAE which is a model mimicking relapsing remitting multiple sclerosis.
- the present disclosure is based in part on the finding that small organic compounds designated herein SM1, SM6, SM7 and SM9 inhibited the activity of bone morphogenetic protein 2 (BMP2) in a cell based assay.
- BMP2 bone morphogenetic protein 2
- These molecules were shown to inhibit disease progression in a relapsing/remitting experimental autoimmune encephalomyelitis (RR-EAE) animal model, a well-established model mimicking multiple sclerosis (MS).
- RR-EAE experimental autoimmune encephalomyelitis
- MS multiple sclerosis
- a pharmaceutical composition comprising a bone morphogenetic protein 2 (BMP2) inhibitor, wherein the BMP2 inhibitor is a small molecule.
- BMP2 bone morphogenetic protein 2
- the pharmaceutical composition is for use in the treatment neuroinflammatory diseases, such as multiple sclerosis.
- a method for treating a neuroinflammatory disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a bone morphogenetic protein 2 (BMP2) inhibitor, wherein the BMP2 inhibitor is a small molecule.
- BMP2 bone morphogenetic protein 2
- the small molecule is having a molecular weight of no more than 1000 gr/mol.
- the small molecule has the Formula (Ia) and salts thereof. According to some embodiments, the small molecule has the formula SM1 and salts thereof. According to some embodiments, the small molecule has the formula SM1 or salts thereof.
- the pharmaceutical composition comprises the compound of Formula (Ia) or a salt thereof:
- a method of treating a neuroinflammatory disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound having the general Formula (Ia) or a salt thereof, wherein X 1 and X 2 are each independently S; X 3 is CN; X 4 , X 5 , X 6 , X 7 , and X 8 are each H; R 1 is H; and R 3 is OR 5 , wherein R 5 is methyl or ethyl.
- the compound is having the formula SM1:
- the pharmaceutical composition is for use in the treatment of a neuroinflammatory disease.
- the pharmaceutical composition further comprises an additional therapeutic agent.
- the neuroinflammatory disease is multiple sclerosis.
- the multiple sclerosis is relapsing remitting multiple sclerosis.
- the method further comprises the administration of an additional therapeutic agent to said subject.
- the additional therapeutic agent is administered prior to, concomitantly, or following the administration of the at least one compound, or a pharmaceutical composition comprising said at least one compound.
- small molecule and "small organic molecule” as used herein are interchangeable and refer to an organic molecule having molecular weight not more than 2000 gr/mol. According to some embodiments, the molecular weight of the small molecule is not more than 1000 gr/mol. According to some embodiments, the molecular weight of the small molecule is not more than 750 gr/mol. According to some embodiments, the molecular weight of the small molecule is not more than 500 gr/mol.
- salt or "a salt thereof' refers to pharmaceutically acceptable salts of the compounds disclosed herein.
- Not limiting examples includes acid addition cationic salts and anionic salts.
- Acid addition cationic salts are typically formed when a compound having a basic atom is exposed to an acidic environment. These include, as a non-limiting examples, ammonium ions, such as those form by protonation of a nitrogen-containing compound.
- anionic salt are typically formed when a compound having a hydrogen atom is exposed to a basic environment. These include, as a non-limiting examples, carboxylates, which may be formed upon deprotonation of a carboxylic acid or saponification of ester; and compounds having a deprotonated nitrogen atom.
- any one groups recited to be “optionally substituted” or otherwise “substituted” is said to have one or more atoms or group of atoms substituting a native atom or group (such as a hydrogen atom) on any of the atoms thereof.
- the invention further provides use of any of the compound herein designated SM1.
- compositions e.g., pharmaceutical compositions comprising at least one compound of Formula (Ia), e.g., compounds herein designated "SM1" and optionally a pharmaceutically acceptable carrier, diluent or excipient.
- the present invention provides pharmaceutical compositions comprising "SM1" and optionally a pharmaceutically acceptable carrier, diluent or excipient for use in the treatment of neuroinflammatory disorders, e.g. multiple sclerosis, neurotoxicity or brain damage.
- the invention also encompasses enantiomers, stereoisomers, or any other isomers of any of the herein recited compounds.
- the therapeutic efficacy of the compounds of the invention or any of their enantiomers, stereoisomers, or isomers can be tested in vitro or in animal models, for example the EAE animal model.
- compositions refers to a preparation of at least one organic small molecule as described herein.
- pharmaceutical compositions of the invention comprise a pharmaceutically acceptable carrier, diluent or excipient.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents and the like and refers to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered small organic compound.
- An adjuvant is included under this term.
- excipient refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient.
- excipients or non-toxic carriers include but are not limited to calcium carbonate, calcium phosphate, various sugars and types of starch, glucose, sucrose, sodium saccharin, mannitol, lactose, cellulose derivatives, gelatin, vegetable oils, magnesium stearate, magnesium carbonate, talcum, polyalkylene glycols, and polyethylene glycols.
- compositions according to the invention may be manufactured by processes well known in the art, using one or more pharmaceutically acceptable carriers, e.g., by means of conventional mixing, dissolving, granulating, emulsifying, encapsulating, entrapping, or lyophilizing processes. Proper formulation is dependent upon the route of administration chosen.
- the pharmaceutical composition may be produced as solid dosage form, e.g. a powder, pill, tablet or the like, or as a solution, emulsion, suspension, aerosol, syrup or elixir.
- treatment refers to clinical intervention in an attempt to alter the natural course of disease in the subject being treated and can be performed either by prophylaxis or during the course of clinical pathology. Desirable effects of treatment include preventing occurrence or recurrence of disease, reduction, alleviation or elimination of symptoms, decreasing the rate of disease progression, amelioration or reduction of the disease severity or state, improved prognosis, delaying the onset of the symptoms of a disease, delaying relapses as well as inducing neurogenesis and myelination.
- EDSS Exponed Disability Status Scale
- FS functional systems
- Each functional system is scored on a scale of 0 (normal) to 5 or 6 (maximal impairment).
- EDSS steps 5.0 to 9.5 are defined by the impairment to walking.
- neuroinflammatory disorder refers to conditions where immune responses damage components of the nervous system.
- MS multiple sclerosis
- NMO neuromyelitis optica
- Inflammatory mechanisms have also been implicated in the pathogenesis of many other CNS disorders including systemic inflammatory conditions with central nervous system involvements such as vasculitis, sarcoidosis, and Behcet disease, as well as neurodegenerative, psychiatric disorders, neurotoxic conditions, stroke and brain injury.
- neurodegenerative disease condition or disorder
- AD Alzheimer's disease
- PD Parkinson's disease
- ALS Amyotrophic Lateral Sclerosis
- the pharmaceutical composition according the invention is for the treatment of a "demyelinating disease".
- demyelinating disease as herein defined is any disease of the nervous system in which the myelin sheath of neurons is damaged or removed resulting in abrogated function of the neuronal cells.
- the neurodegenerative disease according to the invention is multiple sclerosis.
- the pharmaceutical composition according to the invention is for the treatment of multiple sclerosis.
- MS Multiple Sclerosis
- a chronic inflammatory neurodegenerative disease of the central nervous system that destroys myelin, oligodendrocytes and axons.
- MS is the most common neurological disease among young adults, typically appearing between the ages of 20 and 40.
- the symptoms of MS vary, from the appearance of visual disturbance such as visual loss in one eye, double vision to muscle weakness fatigue, pain, numbness, stiffness and unsteadiness, loss of coordination and other symptoms such as tremors, dizziness, slurred speech, trouble swallowing, and emotional disturbances.
- visual disturbance such as visual loss in one eye, double vision to muscle weakness fatigue, pain, numbness, stiffness and unsteadiness
- loss of coordination and other symptoms such as tremors, dizziness, slurred speech, trouble swallowing, and emotional disturbances.
- As the disease progresses patients may lose their ambulation capabilities, may encounter cognitive decline, loss of self-managing of everyday activities and may become severely disabled and dependent.
- MS symptoms develop because immune system elements attack the brain's cells (glia and /or neurons) and damage the protective myelin sheath of axons. The areas in which these attacks occur are called lesions that disrupt the transmission of messages through the brain.
- RRMS Relapsing-remitting MS
- SPMS Secondary-progressive MS
- SPMS relapses may occur, but there is no remission (stabilization) for a meaningful period of time and the disability progressively worsens; (3) Primary-progressive MS (PPMS), which progresses slowly and steadily from its onset and accounts for less than 20 percent of MS cases. There are no periods of remission, and symptoms generally do not decrease in intensity; and (4) Progressive-relapsing MS (PRMS). In this type of MS, people experience both steadily worsening symptoms and attacks during periods of remission.
- PPMS Primary-progressive MS
- PRMS Progressive-relapsing MS
- MS multiple sclerosis
- Treatment usually focuses on strategies to treat MS attacks, manage symptoms and reduce the progress of the disease.
- agents used for the treatment of MS are corticosteroids that are mainly used to reduce the inflammation that spikes during a relapse, beta interferons, which slow the progress of multiple sclerosis, reduce the number of attacks and lessen the severity of attacks, Glatiramer acetate (Copaxone ® ), which reduces the number of MS attacks, Fingolimod (Gilenya ® ), Natalizumab (Tysabri ® ) and other agents known in the art.
- New emerging therapies that reduce the relapse rate and mildly affect disability progress include dimethyl fumarate (BG-12, Tecfidera ® ), teriflunomide (Aubagio ® ), Alemtuzumab (Campath ® 1-H, Lemtrada ® ) and Ocrelizumab (Ocrevus TM ).
- Diagnosis of multiple sclerosis may be performed by any method known in the art and includes lumbar puncture (spinal tap) for cerebrospinal fluid tests, including CSF oligoclonal banding, MRI scan of the brain and MRI scan of the spine (spinal cord) and neuronal pathway function study (evoked potential tests).
- intraperitoneal administration of the small organic compounds of the invention SM1, SM7 and SM9 ameliorated the clinical symptoms in a relapsing/remitting experimental autoimmune encephalomyelitis (RR-EAE) animal model, a well-established model mimicking multiple sclerosis (MS).
- RR-EAE experimental autoimmune encephalomyelitis
- EAE Experimental autoimmune encephalomyelitis
- CNS central nervous system
- MS multiple sclerosis
- ADAM acute disseminated encephalomyelitis
- EAE can be induced in a number of species, including mice, rats, guinea pigs, rabbits and primates. Disease induction is usually done by exposure of the animals to various antigens.
- the most commonly used antigens are spinal cord homogenate (SCH), purified myelin, myelin protein such as myelin basic protein (MBP), myelin proteolipid protein (PLP or lipophilin), and myelin oligodendrocyte glycoprotein (MOG), or peptides of these proteins, all resulting in distinct models with different disease characteristics regarding both immunology and pathology.
- SCH spinal cord homogenate
- myelin protein such as myelin basic protein (MBP), myelin proteolipid protein (PLP or lipophilin)
- MOG myelin oligodendrocyte glycoprotein
- rodents can display a monophasic bout of EAE, a relapsing-remitting form, or chronic EAE.
- the typical susceptible rodent will debut with clinical symptoms around two weeks after immunization and will present symptoms of a relapsing-remitting disease.
- Modeling of multiple sclerosis may be performed with SJL/J Mice.
- This EAE model is induced in 8-week old SJL/J female mice by the proteolipid protein (PLP) fragment (along with Pertussis toxin).
- PLP proteolipid protein
- This model exhibits a relapsing-remitting (RR) disease course, resembling those observed in MS patients.
- Modeling of multiple sclerosis may also be performed using C57BL/6 female mice, in which disease is induced with myelin-oligodendrocyte glycoprotein peptide (MOG).
- MOG myelin-oligodendrocyte glycoprotein peptide
- DAI Disease Activity Index
- the above scoring index may thus be used for monitoring the severity of the disease and the onset of relapses in order to determine the therapeutic effect of the small organic molecules of the invention.
- the compounds of the invention can be used for the treatment of RR-MS.
- the compounds of the invention can be used for the treatment of secondary-progressive MS (SPMS), or primary-progressive MS (PPMS), or progressive-relapsing MS (PRMS).
- SPMS secondary-progressive MS
- PPMS primary-progressive MS
- PRMS progressive-relapsing MS
- the present invention provides a method of treating a multiple sclerosis, the method comprising the step of administering to a subject in need thereof a therapeutically effective amount of "SM1" or a pharmaceutical composition comprising said at least one compound.
- the step of administering a compound of the invention or a pharmaceutical composition of the invention may be performed by, but is not limited to, the following routes of administration: oral, rectal, transmucosal, transnasal, intestinal, or parenteral delivery, including intramuscular, subcutaneous, and intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
- routes of administration including intramuscular, subcutaneous, and intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.
- one may administer the pharmaceutical composition according to the invention in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a tissue region of a subject, e.g. into the affected CNS areas.
- the small organic molecule of the invention is administered in combination with an additional therapeutic agent.
- the additional therapeutic agent may be any therapeutic agent suitable or known for treating multiple sclerosis or for reducing the relapse rate and affecting disability progress.
- Non-limiting examples include Interferon-beta1 (such as Avonex ® , Betaferon ® , Rebif ® ), Glatiramer acetate (Copaxone ® ), Fingolimod (Gilenya ® ), Natalizumab (Tysabri ® ), Ocrelizumab (Ocrevus ® ) and other agents known in the art.
- the additional therapeutic agent may be a cellular therapy including administration of cells including but not limited to mesenchymal stem cells (MSC), MSC-like cells, neural progenitor cells, CD34 + cells, CD133 + cells from all available sources, induced pluripotent stem cells (iPSC), differentiated pluripotent stem cells, and the like.
- MSC mesenchymal stem cells
- iPSC induced pluripotent stem cells
- differentiated pluripotent stem cells and the like.
- said additional therapeutic agent is an agent which mediates opening of the BBB, for example Mannitol, which may be intravenously injected.
- the additional therapeutic agent may be formulated together with the small organic compound of the invention, or be part of a separate composition.
- the additional agent may be administered together with the compounds of the invention or separately. It may be administered prior to, concomitantly or following the administration of the compounds or pharmaceutical compositions of the invention.
- BBB blood brain barrier
- the term "therapeutically effective amount" (or amounts) of the at least one small organic molecule according to the invention is determined by such considerations as are known in the art in order to cure, arrest or at least alleviate the medical condition.
- the precise dose and frequency of administration depends on the severity of the patient's disease, on the route of administration, and on the pharmacokinetics of the compound. Determining the dose is a routine procedure and well known to physicians and other of ordinary skill in the art.
- the dosage or the therapeutically effective amount can be estimated initially from in vitro assays, cell culture assays, and in vivo experiments performed in animal models, e.g. EAE.
- the dosage provided below was estimated based on the EAE mouse model of multiple sclerosis.
- treatment with 10mg/kg or 20mg/kg of each of SM1, SM7 or SM9 ameliorated EAE.
- the symptoms in the treated EAE mice were less severe than those in the controls, at each phase of the study. This effect was also manifested by the fact that in the treated EAE mice group, fewer mice exhibited a more severe form of the disease (i.e. clinical score of 2-5).
- the treatment lead to increasing amount of myelin in spinal cord of EAE mice indicating increased remyelination processes or decreased demyelination in response to these SMs treatment, or both.
- Non-limiting examples of therapeutic dosages include but are not limited to 400-800 mg per about 70 kg human.
- the amount of the small organic molecule to be administered may vary by about 5-25%, in consideration of the molecular weight and other features of a specific agent.
- the term “about” as herein defined refers to a fluctuation of 5-25% of the amount as herein defined.
- the term “about” encompasses variations of +/-10%, more preferably +/-5%, even more preferably +/-1%, and still more preferably +/-0. 1% from a specified value.
- the small organic molecule according to the invention or any pharmaceutical composition comprising same may be administered to a patient at a single or at multiple administrations.
- the small organic molecule or the pharmaceutical composition comprising same may be administered to the patient continuously or for discrete periods of time, as determined by such considerations as known to a person skilled in the art in order to cure, arrest or at least alleviate the medical condition.
- Toxicity and therapeutic efficacy of the small organic molecule described herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals.
- the data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosages for use in human.
- the dosage may vary depending upon the dosage form employed and the route of administration.
- subject as used herein means warm-blooded animals, such as for example rats, mice, dogs, cats, guinea pigs, primates and humans.
- methods of the invention are particularly intended for the treatment of a human subject suffering from a neurodegenerative disease, other mammalian subjects are included.
- subject and patient are used interchangeably herein.
- the present invention also discloses a compound of the formula "SM1" and a pharmaceutically acceptable carrier, excipient or diluent for use in a method of treatment of a subject suffering from multiple sclerosis, wherein said method comprising administering said at least one small organic molecule and a pharmaceutically acceptable carrier to said subject.
- the compounds of the invention were initially selected based on their ability to inhibit BMP-2 signaling in vitro.
- the small organic molecules SM1, SM6, SM7 and SM9 were screened out of a large library for their ability to inhibit BMP-2 in vitro without leading to cytotoxicity in mouse ATDC5 cells.
- these compounds showed an increase in several markers that are indicative of neural differentiation in vitro.
- BMPs bone morphogenetic protein (or proteins)
- BMPs bone morphogenetic protein (or proteins)
- cytokines or metabologens.
- BMPs induce the formation of bone and cartilage, and have multiple roles in embryonic brain development. Twenty BMPs have been discovered to date, of these, six BMPs (i.e. BMP-2 through BMP-7) belong to the Transforming growth factor ⁇ (beta) super family of proteins.
- BMPs that are associated with neuronal proliferation and development.
- Non-limiting examples include BMP-2 and BMP-4.
- the BMP is human BMP.
- BMP-2 bone morphogenetic protein 2
- BMP-2 plays an important role in the development of bone and cartilage. It is involved in the hedgehog pathway, TGF ⁇ signaling pathway, and in cytokine-cytokine receptor interaction. It is involved also in cardiac cell differentiation and epithelial to mesenchymal transition. BMP-2 acts as a disulfide-linked homodimer and was shown to stimulate the production of bone.
- the Bone morphogenetic protein 2 may be human BMP-2, having the NCBI (National Center for Biotechnology Information) accession number NM_001200.2.
- BMP-4 bone morphogenetic protein 4
- This particular family member plays an important role in the onset of endochondral bone formation in humans. It has been shown to be involved in muscle development, bone mineralization, and ureteric bud development. In human embryonic development, BMP-4 is a critical signaling molecule required for the early differentiation of the embryo and establishing of a dorsal-ventral axis.
- BMP-4 is secreted from the dorsal portion of the notochord, and it acts in concert with sonic hedgehog (released from the ventral portion of the notochord) to establish a dorsal-ventral axis for the differentiation of later structures.
- the Bone morphogenetic protein 4 may be human BMP-4, having the NCBI (National Center for Biotechnology Information) accession number P12644.
- BMPs interact with specific receptors on the cell surface, referred to as bone morphogenetic protein receptors (BMPRs). Signal transduction through BMPRs results in mobilization of members of the SMAD family of proteins.
- BMPRs bone morphogenetic protein receptors
- BMP signaling refers to the signaling pathway initiated by binding of a BMP to its receptor and the subsequent cellular processes induced by this binding, e.g., mobilization of members of the SMAD family of proteins.
- Poly-L-lysine (Sigma-Aldrich) was added to 384-well plates and was removed after 30 min of incubation at RT.
- Recombinant human BMP-2 (rhBMP-2, R&D Systems) was then added to each well to a final concentration of 2 ⁇ g/ml.
- ATDC5 cells (Sigma-Aldrich) were harvested, re-suspended in assay medium and added to a final concentration of 2000 cells/well. Finally, heparin (Sigma-Aldrich) was added to a final concentration of 2 ⁇ g/ml.
- the cells were incubated for 48 hours at 37°C with 5% CO 2 in a humidified chamber in the presence or absence of potential small molecule inhibitors of BPM-2. After incubation, ALP levels and cell viability were determined using a completely automated protocol. Cells were washed with PBS, lysed using a lysis buffer containing 0.2% Triton X-100 in PBS supplemented with a protease inhibitor cocktail (Sigma-Aldrich) and incubated for 25min at RT. ALP level was then determined by addition of CDP-Star ® chemiluminescent substrate (Sigma-Aldrich) and measurement of luminescence after incubation for 25 min at RT in the dark. Cell viability was finally determined by addition of CellTiter-Glo ® reagent (Biological Industries) and luminescence measurement after 10 min of incubation.
- EAE Experimental autoimmune encephalomyelitis
- mice also received an intraperitoneal injection of 300 ng pertussis toxin (PTX, from Sigma-Aldrich) in 0.2 ml PBS. A second injection of PTX (300 ng/mouse) was given 48 h later.
- PTX pertussis toxin
- mice were monitored for symptoms of RR-EAE and were scored as follows: “0” for no disease; “1”, tail paralysis; “2”, hind limb weakness; “3”, hind limb paralysis; “4", hind limb and forelimb weakness/paralysis; "5", moribund.
- mice All procedures involving mice were performed according to the guidelines of the Animal Ethical Committee of the Sourasky Medical Center.
- P19 cells were grown in a-minimum essential medium (aMEM) (Gibco) containing 7.5% calf serum, 2.5% fetal calf serum, and 0.4 ⁇ l/ml penicillin-streptomycin (Gibco), at 37°C, 5% CO2. Cells were replenished with fresh medium every 48 h.
- aMEM a-minimum essential medium
- P19 cells were cultured at concentration of 2 ⁇ 10 5 cells/60 mm bacterial dish and were either unstimulated or incubated with the following stimulations:
- the medium including RA, BMP supplements and SMs, was replenished after 48 h.
- aggregates which formed during RA treatment were dispersed enzymatically (0.05% v/v trypsin-0.02% v/v EDTA) and mechanically and plated in tissue culture grade dishes.
- cells were cultured in RA-, BMP- and SM-free medium, which was refreshed every 48 h.
- MAP-2 positive neurons were examined at day 8 (i.e., day 4 post-RA treatment) by immunofluorescence. Briefly, at day 7, cells were re-cultured in 24 well- plates with cover slips at a final concentration of 5 ⁇ 10 4 cells/well.
- P19 cells were seeded in 6-well-plates (3.5 ⁇ 10 5 cells/well). On the following day, the cells were either untreated or treated with 5 ⁇ 10 -7 M RA, 5ng/ml BMP-2 or SMs for 4h. Cells were washed with ice cold PBS, harvested and lysed with ice cold RIPA buffer (Sigma-Aldrich) supplemented with protease inhibitor cocktail and sodium orthovanadate (Na3VO4) as phosphatase inhibitor (Sigma-Aldrich). Protein concentrations were determined using a BCA protein assay kit (Pierce, Rockford, IL).
- Cell lysates (40-60 ⁇ g protein) were separated by 4-15% SDS-PAGE gel electrophoresis and then transferred to nitrocellulose membranes at 0.2A for 2 h.
- the membranes were blocked at room temperature for 1 h in 5% (w/v) non-fat-dried milk and then incubated with anti-phospho-Smad1/5/9, anti-Smad1 (Cell signaling Technology, Beverly, MA, USA) and anti-tubulin (Sigma-Aldrich) antibodies at room temperature for 2 h.
- the membranes were washed and incubated with alkaline phosphatase-conjugated secondary antibody (Jackson Laboratories Immune Research, PA, USA).
- the ATDC5 cell based assay for assessing structure-function relationship of BMP-2 and BMP receptor IA was originally described in Keller et al (Nature Structural & Molecular Biology 2004 11, 481-488 ). In order to screen a large volume of potential therapeutic agents the ATDC5 cell based bioassay for detecting BMP inhibition was adapted for use in high throughput screening.
- the bioassay is based on the stimulation of alkaline phosphatase (ALP) production in mouse ATDC5 cells by administration of BMP-2 and heparin, and measurement of ALP levels in the presence of the potential inhibitors.
- ALP alkaline phosphatase
- Figure 1(A) shows ALP activity in ATDC5 cells in response to stimulation with rhBMP-2 in the presence of heparin.
- the ALP activity was determined by using CDP-Star ® chemiluminescent substrate.
- Figure 1(B) stimulation of the cells with rhBMP-2 reduces cell number. This may be a result of BMP-2- induced chondrogenesis of ATDC5 cells, followed by reduced proliferation.
- Z' is a parameter indicating the significance of the effect, namely how high is the ALP signal in the presence of BMP2 as compared to the level of the signal in the absence of BMP2. The closer Z' is to 1 the difference is higher.
- SM small molecules
- SM1-SM9 The inhibitory activity of SM1-SM9 and their cytotoxic effect on the cell line are shown in Figure 2 .
- the ALP levels and cell viability are shown in Figure 2 as a percentage of the ALP or viability luminescence levels in the presence of BMP-2 without the SM.
- the SM were tested at various concentrations, i.e. at 0.62 ⁇ M, 1.25 ⁇ M, 2.5 ⁇ M, 5 ⁇ M and 10 ⁇ M.
- Table 1 summarizes the chemical name, structure and IC50 values for SM1-SM9.
- Table 1 SM number Maybridge Number Chemical Name
- IC 50 ( ⁇ M) SM1 KM03702 Methyl 3-[(2E)-2-[cyano(thiophen-2-ylsulfonyl)methylidene]hydrazinyl]thiophene-2-carboxylate 2.6 SM2 XBX00117 1,4-Dihydro-3,6-diphenyl-1,2,4,5-tetrazine 8.5 SM3 SEW00102 Ethyl 2-(methylthio)-4-[[[(5-nitro-2-furyl)carbonyl]amino)-1-(2-thienlmethyl)-1H-imidazole-5-carboxylate 2.6 SM4 GK01385 4-(5-nitro-1,3-dioxobenzo(de)isoquinolin-2-yl)-N-[4-(trifluoromethyl)phen
- EAE autoimmune encephalomyelitis
- SM7 has a toxic effect that results in death of most of the treated mice: by the end of the experiment (day 48), 8 mice died in the low dose group of 10 mg/kg and all of the mice died in the high dose group of 20mg/kg.
- SM6 has an effect on the amelioration of severe EAE.
- P19 cells murine embryo-derived teratocarcinoma cells
- RA retinoic acid
- rhBMP-2 bone morphogenetic protein -2
- Neuronal differentiation is marked by the expression of the neuronal marker MAP-2, while the addition of BMP-2 reduces the levels of this marker.
- Addition of the murine anti- BMP-2/4 monoclonal antibody reverses the effect of BMP-2 and induces acquisition of neuronal phenotype.
- SM1, SM7 and SM9 effect of SM1, SM7 and SM9 on the expression of the neuronal marker MAP-2 in P19 cells was examined in the presence of RA and BMP-2. Three concentrations of the molecules were tested: 0.625 ⁇ M, 1.25 ⁇ M and 2.5 ⁇ M.
- MAP-2 + cells No MAP-2 positive cells were observed in absence of any stimulation.
- RA stimulation of P19 cells increased the number of MAP-2 + cells (73.8 ⁇ 6.5%).
- Addition of rhBMP-2 significantly reduced the number of MAP-2 + cells (31.4 ⁇ 4.3%), i.e. blocked neuronal phenotype, whereas addition of the anti- BMP-2/4 mAb reversed the effect of BMP-2 by increasing the number of MAP-2 + cells (83.6 ⁇ 3.5%, p ⁇ 0.01 vs. RA+BMP-2).
- SM1, SM7 and SM9 reversed the effect of BMP-2, and increased the number of MAP-2 + cells (neurons), compared to merely RA+BMP-2 stimulation.
- SM1 induced neuronal phenotype at all examined concentrations, but most notably at the higher concentration of 2.5 ⁇ M (62.2 ⁇ 3.9%, p ⁇ 0.01 vs. RA+BMP-2).
- SM7 which induced neuronal phenotype at both the low and the mild concentrations, particularly at the mild concentration of 1.25 ⁇ M (76.1 ⁇ 3.1%, p ⁇ 0.01 vs. RA+BMP-2). No significant effect was observed for the higher concentration, perhaps because of a toxic effect.
- SM9 was not effective at the low concentration and induced neurogenesis in both the mild and the higher concentrations of 1.25 ⁇ M and 2.5 ⁇ M (76.4 ⁇ 12.6% and 80.6 ⁇ 10.0% respectively, p ⁇ 0.05 vs. RA+BMP-2).
- the canonical BMP signal is known to be mediated via SMAD phosphorylation.
- BMPs transduce signals by binding to complexes of type I and II serine/threonine kinase receptors. Ligand binding induces phosphorylation of the receptors, which then activate canonical signaling via receptor Smads (R-Smads) 1, 5 and 8. R-Smads are phosphorylated by the activated type I receptor. They then complex with Smad4, triggering nuclear translocation [16].
- R-Smads receptor Smads
- BMP-4 neutralization was analyzed using the same bioassay that was used for screening (namely, ATDC5 bioassay with ALP and viability detection), except that for stimulation of ATDC5 cells rhBMP-4 was employed instead of rhBMP-2.
- SM1 and SM6 had the same effect on ALP production induced by BMP-4 and by BMP-2. Both SM7 and SM9 seemed to inhibit BMP-2 slightly more than BMP-4 (for 2.5 ⁇ M SM7- 47.3% inhibition of BMP-2, compared to 29.8% inhibition of BMP-4, and for 2.5 ⁇ M SM9- 29.1% inhibition of BMP-2, compared to 18.9% inhibition of BMP-4).
- mice RR-EAE induced mice were intraperitoneally injected with 250 ⁇ g/mouse (Low-L) or 500 ⁇ g/mouse (High-H) of the small molecules SM1, SM7, SM9, SM6, or the corresponding vehicle.
- the SMs were injected each day starting on day 9 post immunization for 30 days.
- 3 mice of each group were intraperitoneally injected daily with bromo-2'-deoxyuridine (BrdU) starting from day 9 post immunization for 8 following days.
- PrdU bromo-2'-deoxyuridine
- FIGS 11A-11B show immunohistochemical labeling of BrdU + DCX + cells in mice with EAE after treatment with the SMs or with vehicle. Quantification of the BrdU + DCX + cells revealed a significant increased induction in BrdU + DCX + cells in the SGZ by SM9H along with a trend for increased BrdU + DCX + cells induction by SM9L, SM6L and SM7L as compared to treatment with the vehicle.
- Figures 12A-12B show immunohistochemical labeling of BrdU + NeuN + cells in mice with EAE that were treated with SMs or vehicle, using Olympus 8.1 microscope (magnification ⁇ 10). Quantification of BrdU + NeuN + cells revealed a significant increased induction in BrdU + NeuN + cells in the SGZ by SM1H and SM9L treated mice along with a trend for increased BrdU + NeuN + cells induction by SM9H, as compared to the treatment with the vehicle.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (6)
- Composition pharmaceutique de la revendication 1, pour utilisation dans le traitement d'une maladie neuroinflammatoire.
- Composition pharmaceutique pour utilisation selon la revendication 2, dans laquelle le traitement comprend en outre un agent thérapeutique supplémentaire.
- Composition pharmaceutique pour utilisation de l'une des revendications 2-3, dans laquelle la maladie neuroinflammatoire est la sclérose en plaques.
- Composition pharmaceutique pour utilisation de la revendication 4, dans laquelle la sclérose en plaques est une sclérose en plaques récurrente-rémittente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL251949A IL251949A0 (en) | 2017-04-26 | 2017-04-26 | Small organic molecules for use in the treatment of neuro-inflammatory diseases |
PCT/IL2018/050463 WO2018198123A1 (fr) | 2017-04-26 | 2018-04-26 | Petites molécules organiques destinées à être utilisées dans le traitement de troubles neuroinflammatoires |
Publications (4)
Publication Number | Publication Date |
---|---|
EP3615022A1 EP3615022A1 (fr) | 2020-03-04 |
EP3615022A4 EP3615022A4 (fr) | 2021-03-31 |
EP3615022B1 true EP3615022B1 (fr) | 2023-06-07 |
EP3615022C0 EP3615022C0 (fr) | 2023-06-07 |
Family
ID=62454780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18791845.3A Active EP3615022B1 (fr) | 2017-04-26 | 2018-04-26 | Petites molécules organiques destinées à être utilisées dans le traitement de troubles neuroinflammatoires |
Country Status (9)
Country | Link |
---|---|
US (2) | US11103479B2 (fr) |
EP (1) | EP3615022B1 (fr) |
JP (1) | JP6997800B2 (fr) |
CN (1) | CN110869015B (fr) |
AU (1) | AU2018260535B2 (fr) |
CA (1) | CA3061296A1 (fr) |
ES (1) | ES2948767T3 (fr) |
IL (2) | IL251949A0 (fr) |
WO (1) | WO2018198123A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019122202A1 (fr) * | 2017-12-20 | 2019-06-27 | Ecole Polytechnique Federale De Lausanne (Epfl) | Inhibiteurs sting |
MA52812A (fr) * | 2018-06-07 | 2021-04-14 | Disarm Therapeutics Inc | Inhibiteurs de sarm1 |
EP3897670A4 (fr) * | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | Inhibiteurs de sarm1 en combinaison avec des agents neuroprotecteurs |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY109202A (en) | 1992-07-10 | 1996-12-31 | Nihon Nohyaku Co Ltd | Isothiazole derivatives and processes for preparing the same as well as termite controlling agents comprising the same as active ingredient |
IT1313601B1 (it) | 1999-08-05 | 2002-09-09 | Isagro Ricerca Srl | Fenilpirazoli ad attivita' erbicida |
EP1088822A1 (fr) * | 1999-09-28 | 2001-04-04 | Applied Research Systems ARS Holding N.V. | Dérivés de sulfonyl hydrazides pharmaceutiquement actifs |
US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
US6727241B2 (en) | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
GB0306357D0 (en) | 2003-03-20 | 2003-04-23 | Astrazeneca Ab | Chemical compounds |
JP2007517498A (ja) | 2003-10-07 | 2007-07-05 | アステラス製薬株式会社 | 骨形態形成タンパク質(bmp)2a及びその使用 |
US20060217390A1 (en) | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
WO2006124874A2 (fr) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibiteurs de la b-raf kinase |
CN100396667C (zh) | 2006-02-20 | 2008-06-25 | 中国医学科学院医药生物技术研究所 | 一组具有上调骨形成蛋白bmp-2表达活性的五元不饱和杂环化合物 |
TW200817371A (en) | 2006-08-21 | 2008-04-16 | Synta Pharmaceuticals Corp | Compounds for treating proliferative disorders |
WO2008118626A2 (fr) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibiteurs de jnk et procédés pour identifier des inhibiteurs de jnk |
WO2009114180A1 (fr) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibiteurs de la voie de signalisation bmp |
JP2012533545A (ja) | 2009-07-14 | 2012-12-27 | ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド | 肝臓の増殖を増大させる方法 |
RU2012105453A (ru) | 2009-08-11 | 2013-09-20 | Аллерган, Инк. | Изотиозолы для лечения состояний глаз |
JP5725469B2 (ja) | 2010-11-15 | 2015-05-27 | 学校法人北里研究所 | 骨分化阻害剤およびその製造方法 |
WO2013186777A2 (fr) * | 2012-06-14 | 2013-12-19 | The Medical Researth, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Utilisation d'agents bloquants de la signalisation par une protéine morphogénétique osseuse (bmp) pour le traitement de maladies neuroinflammatoires et neurodégénératives |
JP6542192B2 (ja) | 2013-03-14 | 2019-07-10 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | Bmp阻害剤およびその使用方法 |
US20160045609A1 (en) | 2014-08-14 | 2016-02-18 | Mamoun M. Alhamadsheh | Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life |
-
2017
- 2017-04-26 IL IL251949A patent/IL251949A0/en unknown
-
2018
- 2018-04-26 ES ES18791845T patent/ES2948767T3/es active Active
- 2018-04-26 EP EP18791845.3A patent/EP3615022B1/fr active Active
- 2018-04-26 WO PCT/IL2018/050463 patent/WO2018198123A1/fr unknown
- 2018-04-26 CN CN201880043208.8A patent/CN110869015B/zh active Active
- 2018-04-26 AU AU2018260535A patent/AU2018260535B2/en active Active
- 2018-04-26 JP JP2019557789A patent/JP6997800B2/ja active Active
- 2018-04-26 CA CA3061296A patent/CA3061296A1/fr active Pending
- 2018-04-26 US US16/606,114 patent/US11103479B2/en active Active
-
2019
- 2019-10-07 IL IL269894A patent/IL269894B/en unknown
-
2021
- 2021-07-22 US US17/382,664 patent/US11779565B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
ES2948767T3 (es) | 2023-09-18 |
CN110869015A (zh) | 2020-03-06 |
JP2020517678A (ja) | 2020-06-18 |
AU2018260535A1 (en) | 2019-10-31 |
US11103479B2 (en) | 2021-08-31 |
US11779565B2 (en) | 2023-10-10 |
CA3061296A1 (fr) | 2018-11-01 |
EP3615022C0 (fr) | 2023-06-07 |
CN110869015B (zh) | 2023-08-18 |
IL269894B (en) | 2022-03-01 |
JP6997800B2 (ja) | 2022-02-04 |
WO2018198123A1 (fr) | 2018-11-01 |
AU2018260535B2 (en) | 2023-09-28 |
EP3615022A1 (fr) | 2020-03-04 |
US20210393582A1 (en) | 2021-12-23 |
US20200046680A1 (en) | 2020-02-13 |
EP3615022A4 (fr) | 2021-03-31 |
IL251949A0 (en) | 2017-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11779565B2 (en) | Small organic molecules for use in the treatment of neuroinflammatory disorders | |
JP7082186B2 (ja) | プリドピジンによる筋萎縮性側索硬化症の治療方法 | |
KR102149321B1 (ko) | Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료 | |
JP2010528016A (ja) | 細胞を刺激するための方法および組成物 | |
US20070149580A1 (en) | Use of peroxisome proliferator activated receptor delta agonists for the treatment of ms and other demyelinating diseases | |
JP6250728B2 (ja) | α−2Bアドレナリン受容体作動薬を用いて制御性T細胞を活性化する方法 | |
JP6663509B2 (ja) | 神経幹細胞の分化促進用及び保護用の組成物、並びにそれを利用して神経再生を誘導する方法 | |
JP2020513005A (ja) | Ccr3阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物 | |
JP7212781B2 (ja) | 神経保護剤と組み合わせたsarm1の阻害剤 | |
EP1734959A2 (fr) | Methode de traitement de la schizophrenie et / ou des anomalies de la glucoregulation | |
US20030082802A1 (en) | Method for neural stem cell differentiation using 5ht1a agonists | |
JP2021520362A (ja) | 再ミエリン化を増加させるための組成物および方法 | |
KR100923195B1 (ko) | 도파민 d2 수용체에 의한 도파민성 수용체 발달의 조절방법 및 이의 조성물 | |
EP3761982A1 (fr) | Traitement de maladies démyélinisantes | |
KR20230083330A (ko) | 운동 뉴런 질환 및 신경근 접합 장애 치료를 위한 N-(3-(4-(3-(다이이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민 황산염 및 이의 용매화물의 용도 | |
JP2020500197A (ja) | 骨格筋肥大誘発剤としてのlsd1阻害剤 | |
RU2814327C1 (ru) | ПРИМЕНЕНИЕ СУЛЬФАТНЫХ СОЛЕЙ N-(3-(4-(3-(ДИИЗОБУТИЛАМИНО)ПРОПИЛ)ПИПЕРАЗИН-1-ИЛ)ПРОПИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛ-2-АМИНА И ИХ СОЛЬВАТОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ДВИГАТЕЛЬНЫХ НЕЙРОНОВ И НАРУШЕНИЙ НЕРВНО-МЫШЕЧНЫХ СОЕДИНЕНИЙ | |
JP2015503598A (ja) | 治療的使用 | |
KR100991043B1 (ko) | 도파민 d2 수용체에 의한 도파민성 수용체 발달의 조절 방법 및 이의 조성물 | |
CN115364102A (zh) | 一种吡咯并嘧啶类化合物的应用 | |
TW202328081A (zh) | 用於預防或治療夏馬杜三氏病(Charcot-Marie-Tooth disease (CMT))之組合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191007 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210225 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/345 20060101ALI20210219BHEP Ipc: A61K 31/381 20060101AFI20210219BHEP Ipc: A61K 31/435 20060101ALI20210219BHEP Ipc: A61K 31/42 20060101ALI20210219BHEP Ipc: A61P 25/28 20060101ALI20210219BHEP Ipc: A61K 31/165 20060101ALI20210219BHEP Ipc: A61K 31/4178 20060101ALI20210219BHEP Ipc: A61K 31/395 20060101ALI20210219BHEP Ipc: A61K 31/44 20060101ALI20210219BHEP Ipc: A61P 25/00 20060101ALI20210219BHEP Ipc: A61K 31/425 20060101ALI20210219BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20220527 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230130 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1572813 Country of ref document: AT Kind code of ref document: T Effective date: 20230615 Ref country code: DE Ref legal event code: R096 Ref document number: 602018051278 Country of ref document: DE |
|
U01 | Request for unitary effect filed |
Effective date: 20230626 |
|
U07 | Unitary effect registered |
Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT SE SI Effective date: 20230630 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2948767 Country of ref document: ES Kind code of ref document: T3 Effective date: 20230918 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230907 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230908 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20231007 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230607 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602018051278 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20240308 |
|
U20 | Renewal fee paid [unitary effect] |
Year of fee payment: 7 Effective date: 20240424 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20240419 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240419 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20240501 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240524 Year of fee payment: 7 |